| 1 |
NCT03253172 |
Recruiting |
Potassium Supplementation in CKD |
- Renal Insufficiency, Chronic
- Potassium Depletion
- Hypertension
- Hyperkalemia
|
- Dietary Supplement: Potassium Chloride
- Dietary Supplement: Potassium Citrate
- Dietary Supplement: Placebo
|
Interventional |
Not Applicable |
- Erasmus Medical Center
- Dutch Kidney Foundation
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Difference in estimated glomerular filtration rate (eGFR)
- ≥ 30% decrease in eGFR
- Slope analysis (change in eGFR in ml/min/1.73 m2/year)
- (and 11 more...)
|
532 |
All |
18 Years and older (Adult, Senior) |
NCT03253172 |
NL60825.078.17
MEC-2017-226
CP16.01 |
K+ in CKD |
July 1, 2017 |
October 1, 2022 |
October 1, 2023 |
August 17, 2017 |
November 13, 2017 |
|
- Academic Medical Center Amsterdam
Amsterdam, Netherlands - University Medical Center Groningen
Groningen, Netherlands - Leiden University Medical Center
Leiden, Netherlands - Erasmus MC
Rotterdam, Netherlands
|
| 2 |
NCT03265353 |
Recruiting |
Vascular Effects of Dietary Potassium |
- Cardiovascular Risk Factor
|
- Other: Moderate Potassium/Low Sodium Diet
- Other: Moderate Potassium/High Sodium Diet
- Other: High Potassium/High Sodium Diet
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Conduit artery endothelial-dependent dilation
|
75 |
All |
22 Years to 45 Years (Adult) |
NCT03265353 |
487998-8 |
|
July 25, 2013 |
July 25, 2019 |
July 25, 2020 |
August 29, 2017 |
January 30, 2018 |
|
- University of Delaware
Newark, Delaware, United States
|
| 3 |
NCT01818583 |
Recruiting |
Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter |
- Atrial Fibrillation
- Atrial Flutter
|
- Drug: Potassium chloride
- Drug: Glucose 50 MG/ML
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Cardioversion (time and percentage)
- Atrial fibrillation at 3 months follow up visit and during 72 hours ECG-monitoring period.
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT01818583 |
AK-01 |
|
March 2013 |
December 2017 |
March 2018 |
March 26, 2013 |
December 28, 2016 |
|
- Diakonhjemmet Hospital
Oslo, Norway
|
| 4 |
NCT03174860 |
Recruiting |
Effect of Preoperative Diclofenac Potassium on Articaine Buccal Infitration Success |
- Pulpitis - Irreversible
- Anesthesia, Local
|
- Drug: Diclofenac Potassium 50mg Tab
- Drug: Placebo
|
Interventional |
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Success of articaine buccal infiltration.
- Pain on injection
|
66 |
All |
18 Years to 60 Years (Adult) |
NCT03174860 |
CEBC-CU-2016-11-167 |
|
October 2016 |
November 2017 |
December 2017 |
June 5, 2017 |
June 5, 2017 |
|
- Faculty of Dentistry
Cairo, Egypt
|
| 5 |
NCT03229980 |
Recruiting |
Pediatric Myocardial Protection With Potassium Cardioplegia |
|
- Drug: custodiol
- Drug: Cold blood cardioplegia (large volume)
- Drug: Cold blood cardioplegia (small volume)
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Cardiac rhythm on return
- The inotropic score
- Cardiac dysrhythmias
- (and 4 more...)
|
60 |
All |
1 Month to 12 Years (Child) |
NCT03229980 |
IRB00008715918 |
|
August 10, 2017 |
February 2018 |
March 2018 |
July 26, 2017 |
October 19, 2017 |
|
- Faculty of Medicine
Assiut, Egypt
|
| 6 |
NCT03166748 |
Not yet recruiting |
Clinical and Radiographic Assessments of Potassium Nitrate in Polycarboxylate Versus Mineral Trioxide Aggregate as Pulpotomy Biomaterials in Immature Mandibular First Permanent Molars |
- Pulpotomy of Immature Lower First Molar(Apexegenesis)
|
- Combination Product: Potassium Nitrate in Polycarboxylate cement
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- clinical signs and symptoms assessment
- radiographic assessment of root completion
|
50 |
All |
6 Years to 9 Years (Child) |
NCT03166748 |
CBC-CU-2017-0518 |
|
June 2017 |
July 2018 |
August 2018 |
May 25, 2017 |
May 25, 2017 |
|
|
| 7 |
NCT02829879 |
Recruiting |
Effectiveness of Arginin and Potassium Nitrate Dentifrices in Dentin Hypersensitivity Therapy |
|
- Drug: 8% arginine/1450ppm sodium monofluorophosphate dentifrice
- Drug: 5% potassium nitrate/2500ppm sodium fluoride dentifrice
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Differences in mean VAS score per subject
|
50 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02829879 |
FIOUCh 13-103 |
|
December 2015 |
September 2016 |
|
July 12, 2016 |
July 12, 2016 |
|
- Faculty of Dentistry, University of Chile
Santiago, Región Metropolitana, Chile
|
| 8 |
NCT03281928 |
Recruiting |
Effect of Dietary Sodium and Potassium Citrate on Renal Mineral Handling |
|
- Dietary Supplement: Sodium and Potassium Citrate
- Dietary Supplement: Placebo
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
|
52 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03281928 |
IRB17-0992 |
|
October 1, 2017 |
October 31, 2019 |
October 31, 2020 |
September 13, 2017 |
November 1, 2017 |
|
- University of Chicago Medical Center
Chicago, Illinois, United States
|
| 9 |
NCT03096561 |
Recruiting |
Measurement of Serum Potassium Rate During Accidental Hypothermia. |
- Accidental Hypothermia
- Hyperkalemia
- Cardiac Arrest
|
- Diagnostic Test: blood draw from three different vessels
|
Interventional |
Not Applicable |
- University Hospital, Grenoble
- University Grenoble Alps
- Emergency Department, University Hospital Vaudois, Lausanne
- Emergency Department, Hospital of Valais, Sion
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Comparison of potassium rate in central venous blood and blood from a peripheral vein (measured in mmol/l)
- Comparison of potassium rate in venous and arterial blood (measured in mmol/l)
- Comparison of potassium rate from laboratory analysis and at bedside via blood gas analyser (measured in mmol/l)
- (and 3 more...)
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT03096561 |
N° ID-RCB: 2016-A01762-49 |
Kai+ |
November 14, 2016 |
March 2019 |
July 2019 |
March 30, 2017 |
March 30, 2017 |
|
- University Hospital Vaudois
Lausanne, Valais, Switzerland - Hospital of Valais
Sion, Valais, Switzerland
|
| 10 |
NCT03083496 |
Recruiting |
Clinical Evaluation of Different Potassium Oxalate Concentrations in Dentin Hypersensitivity Treatment |
- Dentin Sensitivity
- Hypersensitivity Dentin
- Dentine Hypersensitivity
- Dentin Hypersensitivity
|
- Drug: Potassium Oxalate 5%
- Drug: Potassium Oxalate 10%
|
Interventional |
Not Applicable |
- Federal University of Uberlandia
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
- Fundação de Amparo à Pesquisa do estado de Minas Gerais
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Level of cervical dentin hypersensitivity by using visual analog scale
|
32 |
All |
18 Years to 60 Years (Adult) |
NCT03083496 |
61102016.0.0000.5152 |
|
March 14, 2017 |
June 2017 |
February 2018 |
March 20, 2017 |
March 20, 2017 |
|
- Paulo V Soares
Uberlandia, Federal University of Uberlandia, Brazil
|
| 11 |
NCT03326583 |
Recruiting |
The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia |
- ESRD
- Hyperkalemia
- End Stage Renal Disease
|
|
Interventional |
Phase 2 |
- Dominic Raj
- George Washington University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Gastrointestinal Symptom Rating Scale (GSRS) measuring symptoms from none at all, mild, moderate, and severe through patient interview of participants taking Patiromer in lowering serum potassium levels in ESRD patients with hyperkalemia
- Stopping Patiromer medication of participants
- Adverse events of participants taking Patiromer in lowering serum potassium levels in ESRD patients with hyperkalemia
- (and 2 more...)
|
25 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT03326583 |
071738 |
|
November 1, 2017 |
April 2019 |
April 2020 |
October 31, 2017 |
December 19, 2017 |
|
- DaVita K Street
Washington, District of Columbia, United States
|
| 12 |
NCT03029091 |
Recruiting |
An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) |
|
|
Interventional |
Phase 2 |
- Children's Hospital Medical Center, Cincinnati
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Allergy and Infectious Diseases (NIAID)
- (and 2 more...)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Peak Esophageal Eosinophil Count
- Change in TGF-beta levels
|
15 |
All |
5 Years to 25 Years (Child, Adult) |
NCT03029091 |
2015-9021 |
|
January 19, 2017 |
September 2018 |
August 2019 |
January 24, 2017 |
January 24, 2017 |
|
- University of California, San Diego
La Jolla, California, United States - Northwestern University
Chicago, Illinois, United States - Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
| 13 |
NCT03007160 |
Recruiting |
A Study on the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence |
|
- Drug: Potassium Citrate Extended-release Tablets
|
Interventional |
Phase 4 |
- Dawnrays Pharmaceutical (Holdings) Limited
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Rate of Urolithiasis recurrence
- Time of stone recurrence
- The changes of urine citric acid content compared with baseline
- The changes of Urine pH value compared with baseline
|
2001 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03007160 |
DAWNRAYS101 |
|
July 2016 |
September 2020 |
September 2020 |
January 2, 2017 |
February 1, 2018 |
|
- The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China - The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China - Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China - (and 3 more...)
|
| 14 |
NCT03337477 |
Recruiting |
A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥6.0 . |
|
- Drug: Placebo
- Drug: Sodium Zirconium Cyclosilicate(ZS)
- Drug: Insulin
- Drug: Glucose
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Mean absolute change in S-K from baseline until 4h after start of dosing
- Fraction of patients responding to therapy defined as: S-K <6.0mmol/L between 1 and 4h and S-K <5.0mmol/L at 4h; and no additional potassium lowering therapy from 0 to 4h with exception of the initial insulin treatment at 0h
- Mean absolute change in S-K from baseline to 1 and 2h after start of dosing
- (and 3 more...)
|
132 |
All |
18 Years and older (Adult, Senior) |
NCT03337477 |
D9480C00005
2017-003955-50 |
ENERGIZE |
February 14, 2018 |
September 4, 2018 |
September 4, 2018 |
November 9, 2017 |
April 4, 2018 |
|
- Research Site
Montgomery, Alabama, United States - Research Site
Phoenix, Arizona, United States - Research Site
Los Angeles, California, United States - (and 39 more...)
|
| 15 |
NCT03459911 |
Recruiting |
A Bioequivalence Study of Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) in Normal, Healthy, Adults Under Fasting Conditions |
|
- Drug: Cozaar 100mg Tablet
- Drug: Losartan potassium 100mg
|
Interventional |
Phase 1 |
- Pharmtechnology LLC
- Reliance Life Sciences Private Limited
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Pharmacokinetic parameter for losartan
- To investigate the safety and tolerability of the administration of the two dosage forms
- Other pharmacokinetic parameters for losartan
|
66 |
All |
18 Years to 45 Years (Adult) |
NCT03459911 |
RLS/1117/046 |
|
February 8, 2018 |
March 2018 |
March 2018 |
March 9, 2018 |
March 9, 2018 |
|
- Clinical Unit, Reliance Life Sciences Pvt. Ltd.
Mumbai, Maharashtra, India
|
| 16 |
NCT02591927 |
Not yet recruiting |
Reappraisal of GIK in Acute STEMI by Pre-hospital Administration |
|
- Drug: Glucose-Insulin-Potassium
- Drug: Glucose 5%
|
Interventional |
Phase 3 |
- Centre Hospitalier Universitaire Vaudois
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Infarct size quantified by Late Gadolinium Enhancement using Cardiovascular Magnetic Resonance
- The severity of ischemia/reperfusion injury (myocardial edema, microvascular obstruction and myocardial hemorrhage)
- Major Adverse Cardiovascular Events
- Post-infarction Remodeling
|
334 |
All |
18 Years and older (Adult, Senior) |
NCT02591927 |
32003B_159727 |
REAGIK-STEMI |
February 2016 |
February 2019 |
|
October 30, 2015 |
October 30, 2015 |
|
- Centre Hospitalier Universitaire Vaudois - CHUV
Lausanne, Vaud, Switzerland
|
| 17 |
NCT03195647 |
Recruiting |
Pilot Study for the Tight K Study |
|
|
Interventional |
Phase 3 |
- Barts & The London NHS Trust
- London School of Hygiene and Tropical Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Total number of patients recruited over a 6 month period
- Number of patients successfully randomised into the study to receive standard either usual care or control of potassium at the lower limit of the normal range
- Protocol violation rate
- (and 8 more...)
|
160 |
All |
18 Years and older (Adult, Senior) |
NCT03195647 |
011660 |
TightK |
August 1, 2017 |
April 30, 2018 |
May 31, 2018 |
June 22, 2017 |
March 29, 2018 |
|
- Barts Health NHS Trust
London, United Kingdom - St George's University Hospital London
London, United Kingdom
|
| 18 |
NCT02483702 |
Recruiting |
Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair |
- Graft Versus Host Disease
- Hyperkalemia
- Craniectomy
- (and 3 more...)
|
- Other: Irradiated Blood Transfusions
- Other: Non-Irradiated Blood Transfusions
|
Interventional |
Not Applicable |
- Valley Anesthesiology Consultants
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in extracellular potassium values.
|
20 |
All |
2 Months to 6 Months (Child) |
NCT02483702 |
15-063 |
|
August 2015 |
August 2017 |
|
June 29, 2015 |
November 3, 2016 |
|
- Phoenix Children's Hospital
Phoenix, Arizona, United States
|
| 19 |
NCT03303521 |
Recruiting |
A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients. |
|
- Drug: Placebo
- Drug: Sodium Zirconium Cyclosilicate (ZS)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Proportion of patients who maintain a pre-dialysis serum K between 4.0-5.0 mmol/L on 3 out of 4 dialysis treatments following the long interdialytic interval during the evaluation period and who do not receive rescue therapy during the evaluation period
- Number of patients requiring treatment with insulin/glucose and/or beta adrenergic agonists and/or sodium bicarbonate and/or K binders and/or any form of renal replacement therapy.
- Adverse events (AEs)
- (and 4 more...)
|
180 |
All |
18 Years and older (Adult, Senior) |
NCT03303521 |
D9480C00006
2017-003029-14 |
DIALIZE |
December 14, 2017 |
November 29, 2018 |
November 29, 2018 |
October 6, 2017 |
April 19, 2018 |
|
- Research Site
El Centro, California, United States - Research Site
Long Beach, California, United States - Research Site
Los Angeles, California, United States - (and 63 more...)
|
| 20 |
NCT02523911 |
Recruiting |
Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening |
|
- Drug: Simethicone
- Drug: Placebo
- Drug: sodium sulfate/potassium sulfate/magnesium sulfate solution
|
Interventional |
Not Applicable |
- Mercy Medical Center, Des Moines, Iowa
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Screening
|
- Overall bowel cleansing
- Number of patients with adverse effects
- Number of patients completing the bowel preparation
|
800 |
All |
18 Years and older (Adult, Senior) |
NCT02523911 |
MMC2015-31 |
|
March 2016 |
July 2019 |
July 2019 |
August 14, 2015 |
August 29, 2017 |
|
- UF Health Jacksonville
Jacksonville, Florida, United States - Iowa Endoscopy Center
Clive, Iowa, United States
|
| 21 |
NCT03473158 |
Recruiting |
Fetal Reduction: Mechanical vs Chemical |
|
- Device: Transvaginal ultrasound
- Procedure: Mechanical fetal reduction
- Procedure: Chemical fetal reduction
|
Interventional |
Not Applicable |
- Cairo University
- Riyadh Fertility and Reproductive Health center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Success of the procedure
- Duration of the fetal reduction procedure
- Post-operative vaginal spotting or bleeding
- (and 2 more...)
|
50 |
Female |
18 Years and older (Adult, Senior) |
NCT03473158 |
IVF-001-2018 |
|
August 1, 2017 |
March 2019 |
March 2019 |
March 22, 2018 |
March 22, 2018 |
|
- Cairo University
Cairo, Egypt
|
| 22 |
NCT03169413 |
Not yet recruiting |
Gene Study for Infantile Onset Diabetes |
- Study Genetic Basis of Infantile Onset Diabetes Mellitus
|
- Genetic: Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.
|
Observational |
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Retrospective
|
- Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive potassium channel gene in diabetic patients diagnosed under the age of one year.
- Rate of diabetes mellitus in patients under age of one year attending pediatric endocrinology unit in Pediatric assiut University Hospital
- dentification of possible demographic and environmental risk factors associated with increased risk of diabetes in diabetic patient under the age of one year.
|
100 |
All |
1 Year to 3 Years (Child) |
NCT03169413 |
IDM |
|
January 2018 |
January 2020 |
August 2020 |
May 30, 2017 |
May 31, 2017 |
|
|
| 23 |
NCT03096184 |
Recruiting |
A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers |
- Head and Neck Squamous Cell Carcinoma
|
- Drug: Apatinib Mesylate Tablets
- Drug: Tegafur Gimeracil Oteracil Potassium Capsules
|
Interventional |
Phase 2 |
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival(PFS)
- Overall survival
- Acute toxicity profiles, graded according to the NCI CTCAE version 3.0
|
38 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03096184 |
2017HNRT001 |
|
May 1, 2017 |
October 31, 2018 |
May 1, 2019 |
March 30, 2017 |
March 20, 2018 |
|
- Shanghai ninth people's hospital
Shanghai, Shanghai, China
|
| 24 |
NCT02697292 |
Recruiting |
IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy |
|
- Drug: Intravenous Immunoglobulin
- Drug: Placebo/Normal Saline
|
Interventional |
Phase 3 |
- Mayo Clinic
- Grifols Shared Services North America
- Option Care
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in seizure frequency from Baseline to 5 weeks
|
30 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02697292 |
15-005649 |
|
February 2016 |
February 2018 |
August 2018 |
March 3, 2016 |
August 22, 2017 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
| 25 |
NCT02787304 |
Recruiting |
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) |
- Non-Alcoholic Steatohepatitis
|
- Drug: SHP626
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Subjects Achieving Binary Response on Liver Histology Between Volixibat (SHP626) and Placebo at Week 48
- Change From Baseline to Week 48 on Liver Histology
- Change From Baseline to Week 48 on Hepatic Steatosis
- (and 5 more...)
|
266 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02787304 |
SHP626-201
2016-000203-82 |
|
July 1, 2016 |
July 1, 2020 |
July 1, 2020 |
June 1, 2016 |
July 6, 2017 |
|
- Southern California Research Center
Coronado, California, United States - Fresno Clinical Research Center
Fresno, California, United States - Ceders-Sinai Medical Center
Los Angeles, California, United States - (and 62 more...)
|
| 26 |
NCT02721095 |
Recruiting |
Efficacy of KCl Plus 0.9%NaCl Compare With KCl Plus 0.45%NaCl |
|
- Other: KCl plus 0.9%NaCl
- Other: KCl plus 0.45%NaCl
|
Interventional |
Phase 4 |
- Phramongkutklao College of Medicine and Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with normal serum K as assessed by serum electrolyte
|
84 |
All |
18 Years and older (Adult, Senior) |
NCT02721095 |
PMK1981 |
|
August 2014 |
July 2016 |
September 2016 |
March 28, 2016 |
May 3, 2016 |
|
- Phramonkutklao Hospital
Bangkok, Thailand
|
| 27 |
NCT03405051 |
Recruiting |
Hypokalemia in Hospitalized Patients for Heart Failure in the Therapeutic Cardiac Failure Unit |
|
|
Observational |
|
- Centre Hospitalier Régional Metz-Thionville
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Composite of death and re-hospitalization
- Death
- Re-hospitalization
- (and 3 more...)
|
250 |
All |
Child, Adult, Senior |
NCT03405051 |
2017-03-CHRMT |
HYPIC |
November 15, 2017 |
November 2018 |
February 2019 |
January 19, 2018 |
January 23, 2018 |
|
- CHR Metz-Thionville
Metz, France
|
| 28 |
NCT02825784 |
Recruiting |
A Multicenter Study to Evaluate the Nutritional Suitability of Renastart |
- Chronic Kidney Disease
- Hyperkalemia
|
- Dietary Supplement: Renastart
|
Interventional |
Not Applicable |
- Vitaflo International, Ltd
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in serum potassium level
- Change in height (cm)
- Change in mass (kg)
- (and 3 more...)
|
15 |
All |
up to 10 Years (Child) |
NCT02825784 |
NA-REN-072013-03 |
Renastart |
January 6, 2017 |
June 2018 |
June 2018 |
July 7, 2016 |
February 14, 2018 |
|
- Universitatsklinikum Bonn
Bonn, Germany - Universitatsklinikum Koln
Cologne, Germany - Universitatsklinikum Essen
Essen, Germany
|
| 29 |
NCT03414918 |
Not yet recruiting |
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) |
|
|
Interventional |
Not Applicable |
- University Hospital Padova
- DMG Paris Descartes
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Study 1: Change in Relative Aldosterone Secretion Index (RASI).
- Study 2: Change in plasma aldosterone concentration (PAC).
|
342 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03414918 |
4283/AO/17 |
MAPA |
March 2018 |
January 2019 |
January 2020 |
January 30, 2018 |
January 30, 2018 |
|
- Department of Medicine - DIMED, University of Padova, Italy
Padova, Italy
|
| 30 |
NCT03080831 |
Recruiting |
TOnicity of Perioperative Maintenance SoluTions |
- Thoracic Diseases
- Water-Electrolyte Imbalance
- Fluid Overload
- (and 4 more...)
|
- Drug: NaCl 0.9% in Glucose 5% + 40mmol/L Potassium
- Drug: Glucion 5%
|
Interventional |
Phase 4 |
- Niels Van Regenmortel
- University Hospital, Antwerp
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Fluid balance
- Resuscitation Fluids
- Vasopressor Use
- (and 12 more...)
|
68 |
All |
18 Years and older (Adult, Senior) |
NCT03080831 |
17/4/34 |
TOPMAST-1 |
March 9, 2017 |
December 31, 2017 |
December 31, 2017 |
March 15, 2017 |
May 4, 2017 |
|
- University Hospital, Antwerp
Edegem, Belgium
|
| 31 |
NCT02926989 |
Recruiting |
Intravenous Fluids in Hospitalised Children |
- Hypokalemia
- Hyponatremia
- Hypernatremia
- Dehydration
|
- Drug: Plasmalyte Glucos 50 mg/mL
- Drug: 0.45% saline in 5% dextrose
|
Interventional |
Phase 4 |
- University of Oulu
- Oulu University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of hypokalemia
- Incidence of hyponatremia
- Incidence of hypernatremia
- (and 6 more...)
|
610 |
All |
6 Months to 12 Years (Child) |
NCT02926989 |
EETTMK 48/2016 |
|
October 3, 2016 |
December 2018 |
December 2018 |
October 6, 2016 |
April 19, 2018 |
|
- Oulu University Hospital
Oulu, Finland
|
| 32 |
NCT00835328 |
Recruiting |
Effect of Exendin-(9-39) On Glucose Requirements To Maintain Euglycemia |
- Congenital Hyperinsulinism
|
- Drug: exendin-(9-39)
- Other: placebo
|
Interventional |
Phase 1
Phase 2 |
- Diva De Leon
- Children's Hospital of Philadelphia
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Glucose infusion rate during the last 2 hours of infusion of exendin-(9-39)
- Plasma glucose 1 hour after initiation of infusion,
- Insulin Level
- (and 2 more...)
|
20 |
All |
up to 12 Months (Child) |
NCT00835328 |
2008-10-6256 |
|
February 2009 |
February 2019 |
September 2019 |
February 3, 2009 |
March 9, 2018 |
|
- The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
| 33 |
NCT03087058 |
Recruiting |
Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in serum potassium levels from Baseline to Day 14
- Proportion of subjects with serum K+ levels in the range of 3.8 - 5.0 mEq/L at Day 14 (Initial PD / Dose Finding Phase)
- Proportion of subjects with serum K+ levels in the range of 3.8 - 5.0 mEq/L by visit at any time through Month 6 (Long-Term Treatment Phase)
|
54 |
All |
2 Years to 17 Years (Child) |
NCT03087058 |
RLY5016-206p
2016-002785-31 |
EMERALD |
May 1, 2017 |
July 2020 |
August 2020 |
March 22, 2017 |
February 28, 2018 |
|
- Investigator Site 1111
Sacramento, California, United States - Investigator Site 1108
Stanford, California, United States - Investigator Site 1110
Wilmington, Delaware, United States - (and 35 more...)
|
| 34 |
NCT03034005 |
Recruiting |
The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma |
|
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in airway hyperresponsiveness (mannitol challenge) per change in Na+, K+ pumps content in airway smooth muscle.
- Change in Na+, K+ pump content in airway smooth muscle and in skeletal muscle (ρmol ouabain per g wet weight) in NEA vs. EA.
- Change in airway hyperresponsiveness (PD15 to mannitol) in NEA vs. EA
|
60 |
All |
18 Years to 64 Years (Adult) |
NCT03034005 |
2016-003509-33 |
RECONSTRUCT |
March 27, 2017 |
July 1, 2019 |
July 1, 2019 |
January 27, 2017 |
July 13, 2017 |
|
- Lungemedicinsk forskningsenhed, Bispebjerg Hospital
Kobenhavn, Denmark
|
| 35 |
NCT02765776 |
Not yet recruiting |
An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens in Aged HIV Patients (RalAge) |
|
- Other: Observational retrospective cohort to describe RAL data
|
Observational |
|
- Azienda Policlinico Umberto I
- University of Roma La Sapienza
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Proportion of participants with an HIV-1 viral load < 50 copies/mL
- Change from Baseline in CD4+ T-cell counts
- Change from Baseline in CD8+ t-cell counts, CD8 cell counts
- (and 28 more...)
|
90 |
All |
60 Years and older (Adult, Senior) |
NCT02765776 |
RalAge d'Ettorre 2016 |
RalAge |
May 2016 |
September 2016 |
December 2016 |
May 9, 2016 |
May 9, 2016 |
|
|
| 36 |
NCT03071263 |
Recruiting |
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease |
- Hyperkalemia
- Resistant Hypertension
|
- Drug: Patiromer
- Drug: Placebo
- Drug: Spironolactone
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Treatment group difference (spironolactone plus patiromer vs. spironolactone plus placebo) in proportion of subjects remaining on spironolactone at Week 12
- Treatment group difference in systolic blood pressure (SBP) change by automated office blood pressure (AOBP) measurements from baseline to Week 12 or last available AOBP prior to addition of any new or baseline medications or changes in BP
|
290 |
All |
18 Years and older (Adult, Senior) |
NCT03071263 |
RLY5016-207
2016-002657-38 |
AMBER |
February 13, 2017 |
February 2019 |
May 2019 |
March 6, 2017 |
February 28, 2018 |
|
- Investigator Site 1013
Los Angeles, California, United States - Investigator Site 1015
San Dimas, California, United States - Investigator Site 1012
Hollywood, Florida, United States - (and 57 more...)
|
| 37 |
NCT01942395 |
Recruiting |
Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2) |
- Diastolic Heart Failure
- Hypertensive Heart Disease
|
- Behavioral: DASH/sodium-restricted diet (DASH/SRD)
- Behavioral: Control Diet
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Urinary F2-Isoprostanes
- 24-hour ambulatory blood pressure (mean and diurnal variation)
- Carotid-femoral pulse wave velocity
- (and 5 more...)
|
25 |
All |
50 Years and older (Adult, Senior) |
NCT01942395 |
HUM00052649 |
|
March 2013 |
June 2018 |
December 2018 |
September 16, 2013 |
June 6, 2017 |
|
- University of Michigan
Ann Arbor, Michigan, United States
|
| 38 |
NCT02744456 |
Recruiting |
N-of-1 Trials for Blood Pressure Medications in Adults |
- Hypertension
- High Blood Pressure
|
- Drug: Losartan
- Drug: Amlodipine
- Drug: Hydrochlorothiazide
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Participants satisfied with participating in N-of-1 trial
- Participants satisfied with blood pressure regimen
|
20 |
All |
21 Years to 80 Years (Adult, Senior) |
NCT02744456 |
AAAN9419 |
|
August 2014 |
December 2019 |
June 2020 |
April 20, 2016 |
January 24, 2018 |
|
- Columbia University Medical Center
New York, New York, United States
|
| 39 |
NCT03448549 |
Recruiting |
SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients |
- Colorectal Cancer Stage III
- Adjuvant Chemotherapy
|
- Drug: Oxaliplatin
- Drug: Tegafur，gimeracil and oteracil potassium
- Drug: Xeloda
|
Interventional |
Phase 3 |
- Beijing Cancer Hospital
- Peking Union Medical College Hospital
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Peking University People's Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- 3 year disease free survival
- major adverse event -short term
- major adverse reaction-long term
- (and 2 more...)
|
1191 |
All |
18 Years and older (Adult, Senior) |
NCT03448549 |
PKUCH-C02 |
|
January 1, 2018 |
January 1, 2021 |
January 1, 2024 |
February 28, 2018 |
February 28, 2018 |
|
- Beijing Cancer Hospital
Beijing, Beijing, China
|
| 40 |
NCT03252808 |
Recruiting |
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Japanese Patients With Unresectable Pancreatic Cancer. |
- Pancreatic Cancer Stage III
- Pancreatic Cancer Stage IV
|
- Biological: TBI-1401(HF10)
- Drug: Gemcitabine
- Drug: Nab-paclitaxel
- Drug: TS-1
|
Interventional |
Phase 1 |
- Takara Bio Inc.
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity (DLT)
- Adverse Events (AEs)
- Objective response rate (ORR) by RECIST
- (and 3 more...)
|
76 |
All |
20 Years and older (Adult, Senior) |
NCT03252808 |
TBI1401-03 |
|
September 25, 2017 |
May 31, 2020 |
May 31, 2020 |
August 17, 2017 |
April 24, 2018 |
|
- Clinical Site
Nagoya, Aichi, Japan - Clinical Site
Kashiwa, Chiba, Japan - Clinical Site
Yokohama, Kanagawa, Japan - Clinical Site
Osaka, Japan
|
| 41 |
NCT02253394 |
Recruiting |
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study |
- Pulmonary Arterial Hypertension
|
- Drug: Ambrisentan plus Spironolactone
- Drug: Ambrisentan plus Placebo
|
Interventional |
Phase 4 |
- Brigham and Women's Hospital
- Gilead Sciences
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Other
|
- Combination ambrisentan + spironolactone on cardiopulmonary fitness
- Effect of combination ambrisentan + spironolactone on cardiac output
- Effect of combination ambrisentan + spironolactone on right ventricular function
- (and 2 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02253394 |
CAPS_PAH |
|
September 2015 |
January 2019 |
January 2019 |
October 1, 2014 |
January 18, 2018 |
|
- Brigham & Women's Hospital
Boston, Massachusetts, United States
|
Create an RSS feed from your search for:
Download the search results for: